Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Schering and MediGene begin HPV vaccine trial

Nov. 23, 2000

European Commission grants orphan drug status to Mylotarg for treatment of AML

Nov. 16, 2000

Potential cellular mechanism for adverse cardiac effects of Herceptin described at AHA sessions

Nov. 16, 2000

Independent safety board recommends continuation of Theratope vaccine phase III trial

Nov. 15, 2000

York Medical acquires Norelin from Biostar

Nov. 14, 2000

Data presented at Heat Shock Proteins symposium support clinical application of HspE7

Nov. 10, 2000

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

Nov. 7, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...